Study Group: Physicians who Treat Onychomycosis (US)
Council Members in this Study Group: 121
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Sunil DhawanClinical Assistant Professor of Dermatology
STANFORD UNIVERSITY
Sunil Dhawan, MD, is a Clinical Assistant Professor of Dermatology at Stanford University. He has expertise in clinical dermatology including acne, rosacea, psoriasis, eczema, skin cancer, actinic keratosis, lasers and cosmetic dermatology, and managed...
- Brian Lester
Dermatologist
Brian W Lester, MDBrian Lester, MD, is a Dermatologist in private practice in Massachusetts. His interests include clinical dermatology, cosmetic dermatology, dermatopathology, and dermatologic pharmaceuticals. He has experience with clinical trials involving a variety...
Tim GallagherExecutive Vice President of Pharmacy Operations
ASTRUP DRUG, INC.Tim Gallagher, RPh, is the Executive Vice President of Pharmacy Operations at Astrup Drug in Minnesota, since 1999. Mr. Gallagher manages all aspects of pharmacy operations for the company. He has been a practicing pharmacist for over 25 years in both...
Michele PauporteDermatologist
JUVA SKIN LASER CENTER INCMichele Pauporte, MD, is a dermatologist at Juva Skin and Laser Center, in New York City. Dr. Pauporte's areas of expertise include cosmetic procedures and the treatment of skin cancers, including Mohs micrographic surgery and reconstructive surgery....
Jeffrey WeinbergDirector of Clinical Research - Dermatology
ST LUKE'S-ROOSEVELT HOSPITAL CENTERJeffrey Weinberg, MD, is Director of the Clinical Research Center in the Department of Dermatology at St. Luke's-Roosevelt Hospital Center and Beth Israel Medical Center, both of which are part of the Continuum Health Partners hospital system in New York....
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
November 19, 2009
Leo Pharma completes merger pact with Peplin | www.pharmabiz.com
The recent merger of Peplin with Leo pharma is of some significance and will benefit both companies. It would have been difficult for Peplin to fully develop and market their flagship product alone.
-
Presta Trial shows good results for Enbrel
October 14, 2009
New data from PRESTA trial demonstrate the benefit of Enbrel in patients with psoriasis & psoriatic arthritis | www.pharmabiz.com
This trial showed predicatably good results for Enbrel in patients with psoriasis and psoriatic arthritis. This included improvement in signs and symptoms and quality of life. This will increase sales of Enbrel in the short term. However the two newer agents, Humira and Stelara have better efficacy, and more convenient dosing regimens. Both will be doing similar studies.
-
Starpharma gets US patent for use of VivaGel for protection against STIs
September 29, 2009
Starpharma gets US patent for use of VivaGel for protection against STIs | www.pharmabiz.com
Starpharma's lead product, is a vaginal microbicide gel under development for the prevention of sexually transmitted infections (STIs), including genital herpes and HIV infection. The VivaGel® product concept is designed to offer a safe, convenient and affordable means for women to protect themselves from infection with genital herpes and HIV during sex. Surveys show that there is substantial demand in North America and Europe for such a product with an estimated billion dollar market for STI prevention products in the developed world.
-
Stelara new Option for Psoriasis
September 26, 2009
Stelara Approved to Treat Moderate to Severe Plaque Psoriasis in Adults | www.webmd.com
The FDA approved Stelara based on three studies of 2,266 patients who either got shots of Stelara or a placebo. Patients who got Stelara were more likely to achieve the studies' benchmark for reduction in psoriasis.In a news release, the FDA notes that because Stelara reduces the immune system's ability to fight infections, the product poses a risk of infection. "Serious infections have been reported in patients receiving the product and some of them have led to hospitalization. These infections were caused by viruses, fungi, or bacteria that have spread throughout the body. There may also be an increased risk of developing cancer," the FDA states.
-
Good and Bad From Astellas Joint Venture With Maxygen
July 5, 2009
Astellas Announces Joint Venture with Maxygen to Develop Protein Pharmaceuticals | www.pipelinereview.com
I read this news with great interest. This joint venture called (MPC) will advance Maxy 4 development program for rheumatoid arthritis and transplant rejection. Maxygen & Astellas are committing $ 10 million each for this joint venture. Since I have worked with Astellas (Yamanouchi) and based on my experience, I think this joint venture (JV) is good for shareholders of Maxygen and Astellas but bad for Maxygen employees. I think Maxygen will shift programs and assets to other companies and it's R&D operations and personnel will go to this new JV with Astellas. This will leads to layoff form financial, administrative, corporate and support departments. This press release did not said when and how many pink slips will be handed out. .I think This strategy is already working based on Maxygen stock closed on July 1 at $7.17 up $0.45 (6.7%).
Members in this Study Group include these company types:
- Office Based Private Practice or Clinic
- Academic Medical Center/Hospital or Clinic
- Non-Academic Community Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Owner
- Physician - Director
- President
- Director
- Partner
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| Dermatologists (US) | 616 |
| Physicians who Treat Acne (US) | 302 |
| Podiatrists (US) | 220 |
| Dermatologists who Treat Psoriasis (US) | 106 |
| Physicians who Treat Rosacea (US) | 134 |
| Physicians who Treat Atopic Eczema (US) | 94 |
| Prescribers of Aldara (US) | 84 |
| Physicians who treat Actinic keratoses | 103 |
GLG Live Meetings with this Study Group's Leading Experts (?)
January 25, 2008 | Boston
GLGi: Psoriasis and Medical DermatologyJuly 31, 2007 | San Francisco
GLGi: Drug Delivery TechnologiesGLG Webcasts & Teleconferences
Leading Experts in Physicians who Treat Onychomycosis (US) have not participated in any GLG webcasts.